RT Journal Article
SR Electronic
T1 Trans-ancestral genetic study of diabetes mellitus risk in survivors of childhood cancer: a report from the St. Jude Lifetime Cohort and the Childhood Cancer Survivor Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.02.23290868
DO 10.1101/2023.06.02.23290868
A1 Im, Cindy
A1 Neupane, Achal
A1 Baedke, Jessica L.
A1 Delaney, Angela
A1 Dixon, Stephanie B.
A1 Chow, Eric J.
A1 Mostoufi-Moab, Sogol
A1 Richard, Melissa A.
A1 Gramatges, M. Monica
A1 Lupo, Philip J.
A1 Sharafeldin, Noha
A1 Bhatia, Smita
A1 Armstrong, Gregory T.
A1 Hudson, Melissa M.
A1 Ness, Kirsten K.
A1 Robison, Leslie L.
A1 Yasui, Yutaka
A1 Wilson, Carmen L.
A1 Sapkota, Yadav
YR 2023
UL http://medrxiv.org/content/early/2023/06/05/2023.06.02.23290868.abstract
AB Type 2 diabetes mellitus (T2D) is an established late effect of treatment for childhood cancer. Leveraging detailed cancer treatment and whole-genome sequencing data among survivors of childhood cancer of European (EUR) and African (AFR) genetic ancestry in the St. Jude Lifetime Cohort (N=3,676; 304 cases), five novel diabetes mellitus (DM) risk loci were identified with independent trans-/within-ancestry replication, including in 5,965 survivors of the Childhood Cancer Survivor Study. Among these, common risk variants at 5p15.2 (LINC02112), 2p25.3 (MYT1L), and 19p12 (ZNF492) modified alkylating agent-related risks across ancestry groups, but AFR survivors with risk alleles experienced disproportionately greater risk of DM (AFR, variant ORs: 3.95-17.81; EUR, variant ORs: 2.37-3.32). Novel risk locus XNDC1N was identified in the first genome-wide DM rare variant burden association analysis in survivors (OR=8.65, 95% CI: 3.02-24.74, P=8.1×10-6). Lastly, a general-population 338-variant multi-ancestry T2D polygenic risk score was informative for DM risk in AFR survivors, and showed elevated DM odds after alkylating agent exposures (quintiles: combined OREUR=8.43, P=1.1×10-8; ORAFR=13.85, P=0.033). This study supports future precision diabetes surveillance/survivorship care for all childhood cancer survivors, including those with AFR ancestry.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the US National Cancer Institute (R21 CA261833, C Im/Y Yuan principal investigators; R01 CA216354, Y Yasui/J Zhang principal investigators; U01 CA195547, MM Hudson/K Ness, principal investigators; R01 CA261898, P Burridge/Y Sapkota, principal investigators; U24 CA55727, GT Armstrong, principal investigator; Cancer Center Support [CORE] Grant CA21765, C Roberts, principal investigator), and the American Lebanese Syrian Associated Charities.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Boards for all participating institutions gave ethical approval for this work, including those related to the Childhood Cancer Survivor Study, St. Jude Children's Research Hospital, and the University of Minnesota.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesGenotype and phenotype data for all SJLIFE survivors and a subset of CCSS survivors whose childhood cancer was diagnosed between 1987 and 1999 are accessible through the St. Jude Cloud (https://stjude.cloud). For CCSS survivors diagnosed between 1970 and 1986, genotype data are available through the database of Genotypes and Phenotypes (dbGaP accession number: phs001327.v2.p1) and relevant phenotype data may be requested through https://ccss.stjude.org/.